TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02537379

Intervention type: DRUG
Intervention: COPE
Description: COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
Study: NCT00504335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Capsules
Study: NCT01505881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate low dose
Description: active treatment (low)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 5mg
Description: comparator warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate intermediate dose
Description: active treatment (medium)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 1mg
Description: comparator warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate high dose
Description: active treatment (high)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 3mg
Description: comparator warfarin
Study: NCT03121586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Study: NCT02599818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NavSTAR
Description: Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
Study: NCT00845832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: iv on days 1 and 15 (Parts 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 0.5g iv on days 1 and 15 (Parts 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
Study: NCT03016455

Intervention type: OTHER
Intervention: Presence of DSA w/ cAMR

Intervention type: OTHER
Intervention: Presence of DSA w/o cAMR

Intervention type: OTHER
Intervention: No DSA No cAMR
Study: NCT03961633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARE intervention
Description: will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes.
Study: NCT03906942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW)
Description: FFW consists of videos, games, and content in the form of 152 BET I CAN challenges \[1\]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
Study: NCT00189202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Thymoglobulin induction, sirolimus and no maintenance corticosteroid
Study: NCT00212784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
Study: NCT03156712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
Study: NCT01685788

Intervention type: OTHER
Intervention: No intervention
Study: NCT01800513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Study: NCT03899675

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
Study: NCT02639013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transducer technique
Description: the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
Study: NCT03280836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max.
Study: NCT01760837

Intervention type: OTHER
Group type: OTHER
Intervention: Baked milk products to cow's milk allergic patients
Study: NCT03183999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented ginseng (GINST)
Description: Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
Study: NCT00383513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 360 mg/m\^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
Study: NCT00296907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psychological intervention
Description: Psychoeducation, provision of medical knowledge, coping skills training
Study: NCT04141917

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-care molecular testing and treatment of influenza
Description: Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
Study: NCT05360043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser treatment
Description: All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser treatment
Description: All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
Study: NCT03483662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention
Description: The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
Study: NCT03853655

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative adjuvant radiotherapy
Description: Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week.
Study: NCT01377129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single bundle anterior cruciate ligament reconstruction
Description: Single bundle anterior cruciate ligamentoplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double bundle anterior cruciate ligament reconstruction
Description: Double bundle anterior cruciate ligamentoplasty
Study: NCT04201249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam, lidocaine
Description: Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mesotherapy without drug administration
Description: Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
Study: NCT04144322

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition
Description: Placement of a short implant

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer T3 with DCD Ex Hex Parallel Walled implants
Description: Placement of a long implant with sinus lift and bone graft
Study: NCT03264755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
Study: NCT00082810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given IV
Study: NCT00504335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Capsules
Study: NCT00295139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
Description: Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
Description: Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
Study: NCT01733238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNT2258
Study: NCT00295139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Treatment in Addiction Recovery (STAR)
Description: Manualized substance abuse treatment as usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Description: Case management component
Study: NCT00792623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VarilrixTM
Description: Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
Study: NCT00938145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specimen Ultra-High field MRI
Description: Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specimen Ultra-High field MRI
Description: Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy and Lymphadenectomy
Description: The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy and Lymphadenectomy
Description: The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
Study: NCT04085536

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental and medical treatment
Description: If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
Study: NCT04331964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy
Description: Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial pulpotomy
Description: Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
Study: NCT01378741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
Study: NCT01538836

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss with normal protein intake
Description: Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss with protein supplementation
Description: Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
Study: NCT02378051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staying Strong with Schools Intervention
Description: 1. On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~2. Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Control
Description: Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
Study: NCT00227266

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valproic Acid and Levocarnitine
Description: VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid and Levocarnitine
Description: VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid and Levocarnitine
Description: VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo